Isodiol Last 2 quarters 11 million revenue, small profit, excellent revenue growth, market cap 120 +/- million.
GW Pharma last 2 quarters 11 million revenue. 150 MILLION LOSS, slow revenue growth, market cap 4 Billion +/-. (5.5Bil cad)
Medreleaf last quarter 11 million revenue. 5 million Loss, slow revenue growth, offer by Aurora 3.2 Billion dollars.
Summary Isodiol is growing faster than Both GW Pharma, and Medreleaf by a staggering amount, Isodiol is the only 1 of the 3 with a profit.
Isodiol has 3 Global approvals for their CBD, Germany, the UK, and Brazil. Isodiol's market cap is Pprox 2% of GW Pharma, and 3.5% of medreleaf with far superior fundamentals.
These facts underline Isodiol's grossly undervalued status, especially when you consider the financials referred to above do not include anything from Isodiol's Isosport, Kathy Leland, BSPG, API, South American, Azure bottling, Winn Dixie, Pot of Coffee, Pot of Tea etc, etc, etc sales, all of those sales will not show up until subsequent financial reports.
Isodiol the Disruptive Unicorn is awakening, and the fact that now 4 of our competitors have signed up to buy Isodiol's isolate underlines Isodiol's UNICORN status.
The above evidence can be confirmed using the stockhouse information, and shows Isodiol is undervalued by a multiple of 18 based on current values of GW Pharma and Medreleaf, making FV for Isodiol, $11.52+/- per share pre RS.
Ya I will hold, screaming buy, buy, buy
Isodiol vs. GW Pharma vs. Medreleaf, in case you missed it
Isodiol Last 2 quarters 11 million revenue, small profit, excellent revenue growth, market cap 120 +/- million.
GW Pharma last 2 quarters 11 million revenue. 150 MILLION LOSS, slow revenue growth, market cap 4 Billion +/-.
Medreleaf last quarter 11 million revenue. 5 million Loss, slow revenue growth, offer by Aurora 3.2 Billion dollars.
Summary Isodiol is growing faster than Both GW Pharma, and Medreleaf by a staggering amount, Isodiol is the only 1 of the 3 with a profit.
Isodiol has 3 Global approvals for their CBD, Germany, the UK, and Brazil. Isodiol's market cap is Pprox 4% of GW Pharma, and 8 % of medreleaf with far superior fundamentals.
These facts underline Isodiol's grossly undervalued status, especially when you consider the financials referred to above do not include anything from Isodiol's Isosport, Kathy Leland, BSPG, API, South American, Azure bottling, Winn Dixie, Pot of Coffee, Pot of Tea etc, etc, etc sales, all of those sales will not show up until subsequent financial reports.
Isodiol the Disruptive Unicorn is awakening, and the fact that now 4 of our competitors have signed up to buy Isodiol's isolate underlines Isodiol's UNICORN status.
The above evidence can be confirmed using the stockhouse information, and shows Isodiol is undervalued by a multiple of 18 based on current values of GW Pharma and Medreleaf, making FV for Isodiol, $11.52 +/- per share pre RS.
Ya I will hold, screaming buy, buy, buy